id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-1237-0005,FDA,FDA-2016-E-1237,"Determination of Regulatory Review Period for Purposes of Patent
Extension; SAVAYSA",Notice,Determinations,2017-11-28T05:00:00Z,2017,11,2017-11-28T05:00:00Z,2018-01-30T04:59:59Z,2017-11-28T15:56:38Z,2017-25703,0,0,0900006482cb67b4
FDA-2016-E-1237-0004,FDA,FDA-2016-E-1237,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-08-22T04:00:00Z,2017,8,2017-08-22T04:00:00Z,,2017-08-22T11:38:05Z,,0,0,0900006482a92ef5